Amgen splashes $550M and plans to hire hundreds in manufacturing push into the Tarheel State

Add Amgen to the growing list of biopharma companies taking their business to North Carolina.

The California-based biotech has revealed that it will invest $550 million in a new drug substance manufacturing plant in Holly Springs, N.C., where it will hire hundreds of workers.

If that modest-sized town, 20 miles south of Raleigh, rings a bell, it might be because five months ago, Fujifilm made waves when it unveiled plans to build a massive $2 billion plant there, billed as the largest end-to-end biopharmaceutical manufacturing facility in North America.